CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,787,947 | +751.7% | 228,243 | +416.1% | 0.00% | – |
| Q2 2023 | $796,971 | -19.9% | 44,227 | -28.7% | 0.00% | – |
| Q1 2023 | $995,511 | +431.5% | 61,987 | +505.6% | 0.00% | – |
| Q4 2022 | $187,301 | -73.7% | 10,235 | -71.8% | 0.00% | – |
| Q3 2022 | $713,000 | +202.1% | 36,297 | +186.5% | 0.00% | – |
| Q2 2022 | $236,000 | -86.2% | 12,669 | -83.7% | 0.00% | – |
| Q1 2022 | $1,710,000 | -35.9% | 77,907 | -17.0% | 0.00% | – |
| Q4 2021 | $2,666,000 | +741.0% | 93,832 | +523.6% | 0.00% | – |
| Q3 2021 | $317,000 | – | 15,047 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |